{"entity":{"id":"nct06483334","kind":"trial","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","aka":[],"tldr":"A phase 1/2 trial of Sacituzumab tirumotecan, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) is a phase 1/2 interventional study registered as NCT06483334 by Merck Sharp & Dohme LLC, with 38 participants enrolled, started 2024-07-17 and due to reach its primary completion in 2028-03-31. Interventions recorded: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab and Supportive care measures.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06483334","url":"https://clinicaltrials.gov/study/NCT06483334"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-tirumotecan","enfortumab-vedotin","pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06483334","phase":"1/2","setting":"A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C","sponsor":"Merck Sharp & Dohme LLC","enrolled":38,"outcomes":[]},"route":"/trials/nct06483334/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}